Number of Subjects Who Achieved Complete Remission of Their Disease Day 30 [clinicaltrials_resource:26dc3b1841006f4f9bbb99de455ee89b]
Complete Remission (CR): A CR requires that the following be recorded concurrently: an absolute neutrophil count (segs and bands) > 1000/μL, no circulating blasts, platelets > 100,000/μL; adequate bone marrow cellularity with trilineage hematopoiesis, and < 5% marrow leukemia blast cells. All previous extramedullary manifestations of disease must be absent. If patients continue on with treatment, there can be no evidence of recurrence of ALL for at least 4 weeks.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Number of Subjects Who Achieved Complete Remission of Their Disease Day 30 [clinicaltrials_resource:26dc3b1841006f4f9bbb99de455ee89b]
Complete Remission (CR): A CR requires that the following be recorded concurrently: an absolute neutrophil count (segs and bands) > 1000/μL, no circulating blasts, platelets > 100,000/μL; adequate bone marrow cellularity with trilineage hematopoiesis, and < 5% marrow leukemia blast cells. All previous extramedullary manifestations of disease must be absent. If patients continue on with treatment, there can be no evidence of recurrence of ALL for at least 4 weeks.
Bio2RDF identifier
26dc3b1841006f4f9bbb99de455ee89b
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:26dc3b1841006f4f9bbb99de455ee89b
measure [clinicaltrials_vocabulary:measure]
Number of Subjects Who Achieved Complete Remission of Their Disease
time frame [clinicaltrials_vocabulary:time-frame]
description
Complete Remission (CR): A CR ...... e of ALL for at least 4 weeks.
identifier
clinicaltrials_resource:26dc3b1841006f4f9bbb99de455ee89b
title
Number of Subjects Who Achieved Complete Remission of Their Disease Day 30
@en
type
label
Number of Subjects Who Achieve ...... c3b1841006f4f9bbb99de455ee89b]
@en